Two decades before Bob Chapek was named chief executive of Walt Disney Co. , he identified an unlikely cash gusher: a pack of adorable, talking golden retrievers.

Mr. Chapek was the head of Disney’s home-entertainment division, then riding high on consumers’ seemingly limitless appetite for DVDs. After successfully pumping out direct-to-video sequels to beloved classics like “Bambi” and “The Lion King,” Mr. Chapek sensed an opportunity with “Air Bud,” a 1997 hit film about a basketball-playing dog.

DVDs of the “Air Bud” universe proliferated for 10 sequels and spinoffs released between 1998 and 2013. “Space Buddies,” “Seventh Inning Fetch,” “Snow Buddies” and other titles earned millions for the company. Though nearly all the “Disney Buddies” films were released straight to home video, Mr. Chapek spent extra on orchestral scores, elaborate marketing campaigns and other embellishments usually reserved for major theatrical releases.

Today, the same instincts are benefiting Mr. Chapek as he shepherds Disney’s transition into the streaming age. Much as he did then, Mr. Chapek today must navigate considerable disruption and bridge the old—a library of classic films, TV shows and franchises—with the new: a streaming service considered by Wall Street to be the lifeblood and future of the world’s largest entertainment company.

“Everything he’s doing are things that we did, only in the home-entertainment area,” said Robert Vince, chief executive of Air Bud Entertainment and a producer on all of the “Buddies” films.

This post first appeared on wsj.com

You May Also Like

GM Won’t Take Stake in Nikola

General Motors Co. will no longer take an equity stake in electric-truck…

Amazon Prime Video viewers will have to pay an extra $2.99 monthly in January to avoid ads

Amazon Prime Video viewers seeking to avoid ads during shows and movies…

The Democrat, the Fracking Executive and the Deal They Struck. Can It Work?

Jan. 12, 2024 10:00 am ET Listen (2 min) An unusual agreement…

Covid Antibody Drugs Challenged by Omicron

Preliminary tests indicate the Covid-19 antibody drug cocktail from Regeneron Pharmaceuticals Inc.…